XML 32 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders Equity (Tables)
6 Months Ended
Jun. 30, 2020
Equity [Abstract]  
Schedule of black-scholes option-pricing model

  

Six months ended

June 30, 

 
   2020   2019 
         
Underlying value of share of Common Stock ($)   5.59-6.21    4.91 
Exercise price ($)   5.59-6.21    4.91 
Expected volatility (%)   85.0    93.1 
Term of the option (years)   6.25    6.25 
Risk-free interest rate (%)   0.37-0.52    2.23 
Schedule of options granted to purchase ordinary shares

    For the six months ended June 30, 2020  
    Number of Options    

Weighted average exercise

price

    Aggregate intrinsic value  
          USD      USD in thousands   
Outstanding at the beginning of period     3,143,802       1.09       25,733  
Granted     893,700       6.16          
Forfeited     (41,925 )     2.45          
Exercised     (277,429 )     0.63          
Outstanding at the end of period     3,718,148       3.08       10,484  
Vested at end of period     1,641,346                  
Weighted average remaining contractual life – years as of June 30, 2020     6.92                  
Schedule of outstanding warrants

Warrant   Issuance Date   Expiration Date   Exercise Price
Per Share (USD)
    Number of
Shares of
Common Stock
Underlying
Warrants
 
Private Warrants issued to Yeda (see 1 below)   May 11, 2017   May 11, 2025     (* )     591,382  
Private Warrants issued to founders (see 2 below)   November 27, 2017         -       10,589  
Private Placement Warrants (see 3 below)  

IPO

(December 13, 2018)

  December 13, 2023   11.50       2,900,000  
Public Warrants (see 4 below)  

IPO

(December 13, 2018)

 

October 28,

2024

  11.50       3,500,000  
                      7,001,971  

 

(*) less than $0.001.
Schedule of share-based payment expenses

  

Six months ended

June 30,

 
   2020   2019 
     

Research and development expenses, net

   502    367 
General and administrative   512    264 
    1,014    631 

 

  

Three months ended

June 30,

 
   2020   2019 
     

Research and development expenses, net

   310    173 
General and administrative   367    154 
    677    327